<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02524210</url>
  </required_header>
  <id_info>
    <org_study_id>1208088</org_study_id>
    <secondary_id>2013-004932-31</secondary_id>
    <secondary_id>140096A-21</secondary_id>
    <nct_id>NCT02524210</nct_id>
  </id_info>
  <brief_title>Effect of Inhibitors of the Proton Pump on Intestinal Transporters</brief_title>
  <acronym>BIPP</acronym>
  <official_title>Effect of Inhibitors of the Proton Pump on Intestinal Transporters and Their Impact on the Pharmacokinetics of Dabigatran - Mechanistic and Clinical Approach -BIPP Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dabigatran etexilate is a novel oral anticoagulant. It is indicated in venous thromboembolic&#xD;
      prevention in orthopedic surgery and has recently shown greater efficiency and tolerance as&#xD;
      anticoagulants in preventing thromboembolism in atrial fibrillation. However, it increases&#xD;
      the risk of gastrointestinal bleeding compared to standard treatment (AVK) [3]. In these&#xD;
      circumstances the risk / benefit of dabigatran could be improved by combining it with gastric&#xD;
      protectors such as inhibitor drugs proton pump (IPP).&#xD;
&#xD;
      Investigators want to evaluate the pharmacokinetic and pharmacodynamic effects of&#xD;
      co-administration of these two IPP (omeprazole, rabeprazole) with dabigatran in healthy&#xD;
      subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve (AUC) from plasma concentrations of dabigatran</measure>
    <time_frame>baseline after each dose of dabigatran etexilate.</time_frame>
    <description>Area under the curve (AUC) from plasma concentrations of dabigatran</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve (AUC) from plasma concentrations of dabigatran</measure>
    <time_frame>0.25 hours after each dose of dabigatran etexilate.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve (AUC) from plasma concentrations of dabigatran</measure>
    <time_frame>0.5 hours after each dose of dabigatran etexilate.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve (AUC) from plasma concentrations of dabigatran</measure>
    <time_frame>1 hour after each dose of dabigatran etexilate.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve (AUC) from plasma concentrations of dabigatran</measure>
    <time_frame>1.5 hours after each dose of dabigatran etexilate.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve (AUC) from plasma concentrations of dabigatran</measure>
    <time_frame>2 hours after each dose of dabigatran etexilate.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve (AUC) from plasma concentrations of dabigatran</measure>
    <time_frame>3 hours after each dose of dabigatran etexilate.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve (AUC) from plasma concentrations of dabigatran</measure>
    <time_frame>6 hours after each dose of dabigatran etexilate.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve (AUC) from plasma concentrations of dabigatran</measure>
    <time_frame>8 hours after each dose of dabigatran etexilate.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve (AUC) from plasma concentrations of dabigatran</measure>
    <time_frame>12 hours after each dose of dabigatran etexilate.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve (AUC) from plasma concentrations of dabigatran</measure>
    <time_frame>24 hours after each dose of dabigatran etexilate.</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period &quot; Dabigatran&quot;&#xD;
Washout period (at least 6 days)&#xD;
Period &quot; Rabeprazole + Dabigatran&quot;&#xD;
Washout period (at least 6 days)&#xD;
Period &quot; Omeprazole + Dabigatran&quot;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period &quot;Rabeprazole + Dabigatran &quot;&#xD;
Washout period (at least 6 days)&#xD;
Period &quot; Dabigatran&quot;&#xD;
Washout period (at least 6 days)&#xD;
Period &quot; Omeprazole + Dabigatran&quot;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period &quot; Rabeprazole + Dabigatran&quot;&#xD;
Period &quot; Omeprazole + Dabigatran&quot;&#xD;
Period &quot; Dabigatran&quot;</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran</intervention_name>
    <description>dabigatran etexilate 150 mg/day (1 day)</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rabeprazole and Dabigatran</intervention_name>
    <description>rabeprazole 20 mg / day for 5 days, then the 6th day concomitant rabeprazole 20 mg of dabigatran etexilate 150 mg;</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omeprazole and Dabigatran</intervention_name>
    <description>omeprazole 20 mg / day for 5 days, then the sixth day concomitant omeprazole 20 mg and 150 mg dabigatran etexilate</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  weight between 60 and 85 kg&#xD;
&#xD;
          -  normal clinical exam&#xD;
&#xD;
          -  normal biological exam&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  hypersensitivity to dabigatran or any of its excipients&#xD;
&#xD;
          -  hypersensitivity to omeprazole or rabeprazole or any of its excipients&#xD;
&#xD;
          -  previous history of hemorrhagic disease&#xD;
&#xD;
          -  insufficiency liver&#xD;
&#xD;
          -  severe kidney failure&#xD;
&#xD;
          -  peptic ulcer&#xD;
&#xD;
          -  Any drug taken during the week before the start of the study&#xD;
&#xD;
          -  smoker&#xD;
&#xD;
          -  Consumption of grapefruit juice&#xD;
&#xD;
          -  practice of violent sport&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurent BERTOLETTI, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de SAINT-ETIENNE</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de SAINT-ETIENNE</name>
      <address>
        <city>Saint-etienne</city>
        <zip>42000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>August 13, 2015</study_first_submitted>
  <study_first_submitted_qc>August 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2015</study_first_posted>
  <last_update_submitted>January 22, 2016</last_update_submitted>
  <last_update_submitted_qc>January 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omeprazole</mesh_term>
    <mesh_term>Rabeprazole</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

